Pathway-Directed Therapy in Multiple Myeloma.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple Myeloma (MM) is a plasma cell malignancy with significant unmet needs, especially in relapsed/refractory cases.
• Deregulated signaling pathways, including RAS/RAF/MEK/ERK and PI3K/AKT, are critical in MM pathophysiology and represent promising therapeutic targets.

Purpose of the Study:

• To review emerging targeted therapies for Multiple Myeloma based on deregulated signaling pathways.
• To highlight the potential of rationally derived compounds and precision medicine approaches in MM treatment.

Main Methods:

• Review of current literature on signaling pathways in MM.
• Analysis of therapeutic strategies targeting specific molecular abnormalities.
• Discussion of ongoing precision medicine trials in MM.

Main Results:

• Targeting mutated BRAF (e.g., BRAFV600E) with MEK inhibitors has shown remarkable responses in selected MM patients.
• AKT inhibition demonstrates therapeutic promise as monotherapy or in combination strategies to resensitize MM cells.
• Emerging strategies focus on targeting transcription factors like p53 and c-MYC.

Conclusions:

• Targeted therapies directed at specific signaling pathways represent a promising frontier in MM treatment.
• Precision medicine, informed by pathway biology, is poised to significantly alter future MM therapeutic strategies.
• Further research and clinical trials are essential to fully realize the potential of these targeted approaches.